Biomaterial Database

Tranexamic acid: a new option for heavy menstrual bleeding. 2012

Jeanne M Wilton

Heavy menstrual bleeding, or menorrhagia, af ects approximately one-third of women. Treatments have included nonsteroidal anti-inflammatories and oral contraceptives, although neither is approved by the Food and Drug Administration (FDA) specifically for this use. Lysteda® (tranexamic acid) has recently been approved as a treatment for heavy menstrual bleeding. This article gives a background on menorrhagia and describes treatment with tranexamic acid, including its implications for nurses.

UI	MeSH Term	Description	Entries
D008595	Menorrhagia	Excessive uterine bleeding during MENSTRUATION.	Hypermenorrhea,Heavy Menstrual Bleeding,Heavy Periods,Heavy Period,Menstrual Bleeding, Heavy
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000933	Antifibrinolytic Agents	Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders.	Antifibrinolysin,Antifibrinolysins,Antifibrinolytic,Antifibrinolytic Agent,Antiplasmin,Antiplasmins,Antifibrinolytics,Plasmin Inhibitor,Plasmin Inhibitors,Agent, Antifibrinolytic,Agents, Antifibrinolytic,Inhibitor, Plasmin,Inhibitors, Plasmin
D014148	Tranexamic Acid	Antifibrinolytic hemostatic used in severe hemorrhage.	AMCHA,AMCA,Amchafibrin,Anvitoff,Cyklokapron,Exacyl,KABI 2161,Spotof,Transamin,Ugurol,t-AMCHA,trans-4-(Aminomethyl)cyclohexanecarboxylic Acid
D014481	United States	A country in NORTH AMERICA between CANADA and MEXICO.
D014486	United States Food and Drug Administration	An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.	Food and Drug Administration (U.S.),USFDA,Food and Drug Administration,United States Food, Drug Administration
D016896	Treatment Outcome	Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.	Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D017277	Drug Approval	Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.	Drug Approval Process,New Drug Approval,Food and Drug Administration Drug Approval,Food and Drug Administration Drug Approval Process,New Drug Approval Process,Approval Process, Drug,Approval Processes, Drug,Approval, Drug,Approval, New Drug,Approvals, Drug,Approvals, New Drug,Drug Approval Processes,Drug Approval, New,Drug Approvals,Drug Approvals, New,New Drug Approvals,Process, Drug Approval,Processes, Drug Approval